Oxbryta, which has been a daily oral therapy for the treatment of the haemolytic anaemia that has been associated with the sickle cell disease (SCD), and it has now been available to all the eligible patients across the United Kingdom under the early access program.
The therapy has also received a positive scientific opinion by the MHRA (Medicines and Healthcare Products Regulatory Agency) of the United Kingdom under the EAMS (Early Access to Medicines Scheme.
Arvind Agarwal, medical director at Global Blood Therapeutics (GBT) of United Kingdom and the developer of the Oxbryta said that, this decision of the medicine regulators of the United Kingdom has been responsible for marking a significant milestone for the community of the sickle cell in the United Kingdom.
He also said that, the Early Access to Medicines Scheme has been a positive scientific opinion and it has also been a key step for the purpose of meeting the goal of the company for providing the patients across the United Kingdom with the very first option of the oral treatment that has been inhibiting the red blood cell from sickling and it is having the potential for decreasing the chronic and acute complications of the sickle cell disease.
He also added that, the company ‘GBT’ has been very delighted with the progress in helping the eligible patients to have access to the innovation approach as early as possible.
